|
Division
of Metabolic and Endocrine Drug Products
Review Teams
The review team includes the following:
The following groups may also be consulted
during the review process:
- The Endocrinologic and Metabolic Drugs Advisory Committee
- The Nonprescription Drug Advisory Committee
- The Drug Abuse Potential Advisory Committee
- The Carcinogenicity Assessment Committee
- Division of Drug Marketing, Advertising, and Communications
You can click on any of the underlined
disciplines listed above to see a list of the reviewers names and their areas of specialty.
Back
to Top
DMEDP Home
Date created: October 28, 2004 |
|